Appian Corp (APPN) Stock Price Today
Aura AI Summary
Key Stats
- $2.65BMarket Cap
- -Volume
- TechnologySector
- $45.6452W High
- $18.7252W Low
- -Typical Hold Time
- $2.78BEnterprise Value
- -Div Yield
- -Trading Activity
Track Appian Corp (APPN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Appian Corp has traded between a low of $18.72 and a high of $45.64, highlighting its annual price range. Buy and sell Appian Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Most Recent News
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
Life360 director Morin Brit sells 15,582 shares for $1 million
Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...
AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.